Controlling the burden of liver disease through integration Hepatitis A and B vaccination into National Immunization programs of the EAC Partner States.

dc.contributor.author	EAC
dc.date.accessioned	2021-06-16T09:09:57Z
dc.date.available	2021-06-16T09:09:57Z
dc.date.issued	2018-04
dc.description	Pages 2, colored pictures. includes bibliographic references.	en
dc.description.abstract	Liver cancer is the leading cause of deaths in world. Chronic hepatitis B causes 80% of liver cancer causes in the EAC region. The combination of Aflatoxin exposure with hepatitis infection especially among people, who are malnourished or living with HIV results in a double disease burden that increases disease severity, reduces survivability and heightens liver cancer prevalence. The economic losses of residents of all EAC Partner States associated with morbidity and mortality from Aflatoxin-attributable liver cancer is of high magnitude.	en
dc.description.sponsorship	This policy brief was produced by the East African Community based on Technical Papers developed under the EAC Aflatoxin Prevention and Control Project funded by USAID East Africa Regional Economic Integration Office with technical backstopping from the International Institute of Tropical Agriculture (IITA).	en
dc.identifier.uri	https://repository.eac.int/11671/24113
dc.language.iso	en	en
dc.publisher	EAC	en
dc.relation.ispartofseries	EAC Policy Brief of Aflatoxin Prevention and Control;No. 4, 2018
dc.subject	Aflatoxin	en
dc.title	Controlling the burden of liver disease through integration Hepatitis A and B vaccination into National Immunization programs of the EAC Partner States.	en
dc.type	Policy	en

Files

Now showing 1 - 2 of 2

Now showing 1 - 1 of 1